It is hard to believe that the industry could agree to what is included in the options paper - a new and complex accelerated funding pathway, which would be rarely used, in return for more power for advisory committees and decision-makers, a formal disinvestment framework, and new pricing policies.
A radical reworking of decision-making in the government's favour and it must be resisted
January 28, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 29 August
August 29, 2025 - - Podcast -
Government pressed on diabetes inquiry response as obesity costs soar
August 29, 2025 - - Latest News -
NDIS quarterly report presents a positive picture, but questions remain
August 29, 2025 - - Latest News -
Wesfarmers Health delivers growth as Priceline drives consumer momentum
August 29, 2025 - - Latest News -
'We can evade reality, but we cannot evade the consequences of evading reality'
August 29, 2025 - - Latest News -
Australians fear the loss of independence as vision health concerns rise
August 29, 2025 - - Latest News -
Coalition turns debate on cheaper medicines Bill to HTA reform delays
August 27, 2025 - - Latest News